Get the Stockscreener App
37.01
1.45%
0.53
Revolution Medicines Inc stock is traded at $37.01, with a volume of 1.09M.
It is up +1.45% in the last 24 hours and down -3.29% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$36.48
Open:
$36.63
24h Volume:
1.09M
Relative Volume:
0.50
Market Cap:
$6.92B
Revenue:
$29.52M
Net Income/Loss:
$-567.06M
P/E Ratio:
-10.11
EPS:
-3.66
Net Cash Flow:
$-551.11M
1W Performance:
+1.90%
1M Performance:
-3.29%
6M Performance:
-10.47%
1Y Performance:
-14.45%
1-Day Range:
$36.47
$37.91
1-Week Range:
$35.42
$37.91
52-Week Range:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
37.01 | 6.81B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
RSI Crosses Above 30 for Revolution Medicines Inc. — Reversal in Sight2025 Dividend Review & Low Risk Profit Maximizing Plans - thegnnews.com
Revolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategy - MSN
Healthcare Sector Analysts Offer Insights on Revolution Medicines, Astria Therapeutics, and AbbVie - AInvest
Revolution Medicines’ SWOT analysis: promising cancer drug stock faces pivotal year - Investing.com
LifeSci Capital Initiates Revolution Medicines at Outperform With $80 Price Target - MarketScreener
Will Revolution Medicines Inc. Equity Warrant Bounce From 52 Week Low2025 Retail Activity & Weekly Setup with High ROI Potential - metal.it
What is Revolution Medicines Inc.’s valuation compared to sector2025 Major Catalysts & Weekly Return Optimization Plans - thegnnews.com
Wells Fargo Initiates Revolution Medicines at Overweight With $67 Price Target - MarketScreener
Revolution Medicines initiated with an Overweight at Wells Fargo - TipRanks
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress - MSN
Barclays Reaffirms Buy Rating on Revolution Medicines with $72 Price Target - AInvest
Revolution Medicines’ SWOT analysis: stock poised for growth amid clinical progress - Investing.com Canada
Is It Too Late to Sell Revolution Medicines Inc. Equity WarrantJuly 2025 EndofMonth & Step-by-Step Trade Execution Guides - mustnews.co.kr
Revolution Medicines Inc. Stock Poised for Technical Comeback2025 Key Highlights & AI Forecast Swing Trade Picks - beatles.ru
Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: FibroGen (FGEN), Revolution Medicines (RVMD) - The Globe and Mail
Revolution Medicines’ Earnings Call: Progress Amid Challenges - TipRanks
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $56 to $80 - 富途牛牛
Revolution Medicines (RVMD): A High-Risk, High-Reward Biotech Play in the RAS Oncology Space - AInvest
Contradictions Unveiled: RASolute 302 Study Progress and Efficacy Concerns in Latest Earnings Call - AInvest
Revolution Medicines Forecasts $1.03B-$1.09B Net Loss for 2025 Amid RAS Portfolio Expansion - AInvest
Earnings call transcript: Revolution Medicines Q2 2025 sees stock dip after earnings miss - Investing.com
Revolution Medicines August 2025 slides: advancing RAS inhibitor pipeline with promising data - Investing.com India
Revolution Medicines August 2025 slides: advancing RAS inhibitor pipeline with promising data By Investing.com - Investing.com South Africa
Revolution Medicines Advances RAS-Targeted Therapies, Reports Q2 Earnings - AInvest
Revolution Medicines Advances RAS-Targeted Therapies - TipRanks
Revolution Medicines Q2 2025 Earnings Call Transcript - MarketBeat
Revolution Medicines shares rise 2.13% after-hours after reporting strong Phase 3 trial progress and $2 billion funding agreement. - AInvest
Transcript : Revolution Medicines, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Revolution Medicines Doubles Down On Losses To Fuel New Drugs - Finimize
Earnings Flash: (RVMD) Revolution Medicines Q2 Loss $1.31 Vs. FactSet Est. $1.12 Loss - MarketScreener
Revolution Medicines Reports Wider Q2 Loss, Receives Breakthrough Therapy Designation for Elironrasib - AInvest
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewswire
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 - The Globe and Mail
Tango (TNGX) Q2 Revenue Drops 52% - The Motley Fool
Revolution Medicines shares rise 2.80% intraday after Tango Therapeutics reported dosing first patient in combination trial with Revolution Medicines RAS(ON) inhibitors. - AInvest
What To Expect From Revolution Medicines Inc (RVMD) Q2 2025 Earnings - Yahoo Finance
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
Recovery Setup Building in Revolution Medicines Inc. Experts SayLow Risk Equity Screener With Results Shared - metal.it
What analysts say about Revolution Medicines Inc. stockInvest smarter and grow your wealth faster - Jammu Links News
What drives Revolution Medicines Inc. stock priceDiscover high-growth stocks for your portfolio - Jammu Links News
When is Revolution Medicines Inc. stock expected to show significant growthExplosive returns - Jammu Links News
Is it the right time to buy Revolution Medicines Inc. Equity Warrant stockCapitalize on market trends with confidence - Jammu Links News
How does Revolution Medicines Inc. compare to its industry peersSuperior stock growth - Jammu Links News
What is Revolution Medicines Inc. company’s growth strategyUnmatched market gains - Jammu Links News
Is Revolution Medicines Inc. a growth stock or a value stockRapidly growing investment returns - Jammu Links News
Published on: 2025-08-03 19:52:18 - Jammu Links News
Is Revolution Medicines Inc. Equity Warrant a growth stock or a value stockHigh-yield capital appreciation - Jammu Links News
How strong is Revolution Medicines Inc. company’s balance sheetDiscover high-return stocks for your portfolio - Jammu Links News
How many analysts rate Revolution Medicines Inc. Equity Warrant as a “Buy”Harness the power of proven investment plans - Jammu Links News
How volatile is Revolution Medicines Inc. Equity Warrant stock compared to the marketAccelerated earnings growth - Jammu Links News
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Revolution Medicines Inc Stock (RVMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cislini Jeff | General Counsel |
Jun 20 '25 |
Sale |
39.61 |
1,912 |
75,736 |
54,093 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):